Alpine Immune Sciences. has filed a patent for variant CTLA-4 polypeptides and immunomodulatory proteins that can be used for treating autoimmune or inflammatory conditions. The patent also covers the compositions and methods for making and using these proteins. The variant CTLA-4 polypeptide described in the claim includes specific amino acid substitutions in the extracellular domain. GlobalData’s report on Alpine Immune Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Alpine Immune Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alpine Immune Sciences, Personalized cancer vaccines was a key innovation area identified from patents. Alpine Immune Sciences's grant share as of September 2023 was 19%. Grant share is based on the ratio of number of grants to total number of patents.

Variant ctla-4 polypeptides with amino acid substitutions in extracellular domain

Source: United States Patent and Trademark Office (USPTO). Credit: Alpine Immune Sciences Inc

A recently filed patent (Publication Number: US20230250152A1) describes a variant CTLA-4 polypeptide that has potential applications in immunomodulation and treatment of diseases associated with an overactive immune response. The variant polypeptide includes one or more amino acid substitutions in the extracellular domain of the unmodified CTLA-4 polypeptide or a specific binding fragment thereof. These substitutions are selected from a list of specific amino acids, such as M87T, L12F, R16H, and others.

The patent also describes an immunomodulatory protein that includes the variant CTLA-4 polypeptide and a multimerization domain. The multimerization domain can be an Fc domain or a variant thereof with reduced effector function. The Fc domain can have specific amino acid modifications, such as L234A/L235E/G237A. The immunomodulatory protein has the ability to block the binding of CD80 and/or CD86 to CD28 on T cells.

Furthermore, the patent discusses the use of the variant CTLA-4 polypeptide and the immunomodulatory protein in pharmaceutical compositions for modulating immune responses and treating diseases or conditions associated with an overactive immune response. These compositions can be administered to subjects in various forms, such as conjugates, nucleic acid molecules, vectors, cells, or infectious agents.

The patent also covers methods of producing the variant CTLA-4 polypeptide or the immunomodulatory protein by introducing the corresponding nucleic acid molecule into host cells and isolating or purifying the protein. Additionally, the patent describes methods of modulating immune responses and treating diseases or conditions by administering the pharmaceutical compositions to subjects.

Overall, this patent presents a novel variant CTLA-4 polypeptide and its applications in immunomodulation and disease treatment. The inclusion of specific amino acid substitutions and the use of multimerization domains enhance the binding affinity and functionality of the polypeptide. The patent provides a comprehensive framework for the development and use of these immunomodulatory proteins in various therapeutic applications.

To know more about GlobalData’s detailed insights on Alpine Immune Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies